VM-26联合氯尼达明用于经治小细胞肺癌的II期研究。
A phase II study of VM-26 plus lonidamine in pretreated small cell lung cancer.
作者信息
Gridelli C, De Marinis F, Rossi A, Tucci E, D'Aprile M, Cioffi R, Cortesi E, Migliorino R, Pisano A, Scognamiglio F, Di Giacomo R, Bianco A R
机构信息
Divisione di Oncologia Medica B, Istituto Nazionale Tumori, Napoli, Italy.
出版信息
Anticancer Res. 1997 Mar-Apr;17(2B):1277-9.
BACKGROUND
SCLC relapsing or refractory after induction chemotherapy is a chemoresistant tumor. The outcome of salvage chemotherapy is poor, with low response rates (< 30%) and short survival times (3-4 months). The development of drug resistance is considered the major cause of failure of treatment. VM-26 is one of the most active drugs in SCLC. Lonidamine has shown to enhance in both vivo and vitro antitumor activity of several cytotoxic drugs acting on drug resistance mechanisms.
MATERIALS AND METHODS
VM-26 and lonidamine were employed as salvage chemotherapy in 30 small cell lung cancer patients. The doses of chemotherapy used were: VM-26 100 mg/m2, i.v., days 1 to 3; lonidamine 600 mg, p.o., days 1 to 5, recycled every 3 weeks.
RESULTS
We observed 13.3% of objective response and a median survival of 4 months. All the responses were obtained in patients relapsing after a response to induction chemotherapy. Toxicity was moderate with no toxic death.
CONCLUSIONS
Our study shows that Lonidamine failed to increase the VM-26 activity in pretreated small cell lung cancer patients.
背景
诱导化疗后复发或难治的小细胞肺癌是一种化疗耐药肿瘤。挽救性化疗的结果较差，缓解率低（<30%）且生存时间短（3 - 4个月）。耐药的发生被认为是治疗失败的主要原因。威猛（VM - 26）是小细胞肺癌中最有效的药物之一。氯尼达明已显示出可增强几种作用于耐药机制的细胞毒性药物在体内和体外的抗肿瘤活性。
材料与方法
30例小细胞肺癌患者采用威猛（VM - 26）和氯尼达明进行挽救性化疗。化疗使用剂量为：威猛（VM - 26）100mg/m²，静脉注射，第1至3天；氯尼达明600mg，口服，第1至5天，每3周重复一次。
结果
我们观察到客观缓解率为13.3%，中位生存期为4个月。所有缓解均出现在诱导化疗有反应后复发的患者中。毒性为中度，无毒性死亡。
结论
我们的研究表明，氯尼达明未能增加预处理的小细胞肺癌患者中威猛（VM - 26）的活性。
Zotero 插件